Stay updated with breaking news from Primary Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up
Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI...
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results
/PRNewswire/ -- Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients...